Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001; 104: 2996-3007
28． Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005; 112: 1825-1852 29． 高野照夫 心不全の新しい考え方と治療の進歩 日臨麻
誌1996; 16: 326-332
30． Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure.
N Engl J Med. 2001; 345: 1435-1443
31． Zelis R, Kinney EL, Flaim SF, et al. Morphine: Its use in pulmonary edema. Cardiovasc Rev Rep. 1981; 2: 257-267 32． Ellison DH. Diuretic therapy and resistance in congestive
heart failure. Cardiology. 2001; 96: 132-143
33． Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996; 28: 376-382
34． Murry MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001; 111:
513-520
35． Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717 36． Brown NJ. Eplerenone: cardiovascular protection. Circulation.
2003; 107: 2512-2518
37． Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321
38． Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543-551
39． Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001; 104: 2417-2423
40． Cotter G, Metzkor E, Kaluski E, et al. Randomized trial of high-dose isosorbide nitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide nitrate in severe pulmonary oedema. Lancet. 1998; 351: 389-393
41． Serizawa T, Hirata Y, Kohmoto O, et al. Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J. 1988; 29: 143-149 42． Burger AJ, Horton DP, LeJemtel T, et al. Prospective
randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002; 144: 1102-1108 43． Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not
improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004; 110: 1620-1625.
44． Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111: 1487-1491 45． Hamilton RJ, Carter WA, Gallagher EJ. Rapid improvement
of acute pulmonary edema with sublingual captopril. Acta Emerg Med. 1996; 3: 205-212
46． Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol. 1985; 56: 896-904.
47． The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533
48． 村上元孝，木村栄一，新谷博一，他 ポンプ不全に対す るドブタミン，ドパミンの薬剤効果の比較―多施設共同研 究の比較― 最新医学 1984; 39: 1657-1671
49． O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999; 138: 78-86
50． Seino Y, Momomura S, Takano T, et al. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Crit Care Med. 1996; 24: 1490-1497
51． 清野精彦：急性心不全の病態と内科的治療.進歩する心 臓研究1994; 24; 37-45
52． Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001; 81: 141-149
53． Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202
54． Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23: 1422-1432
55． 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005; 112(Suppl 24): IV1-IV203
56． The CONSENSUS trial group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS). New Engl J Med. 1987; 316: 1429-1435 57． The SOLVED Investigators. Effect of enalapril on survival in
patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 1991; 325: 293-302 58． Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril
on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669-677
59． Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-766 60． Suzuki S, Yoshimura M, Nakayama M, et al. Plasma levels of
B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-time follow-up analysis.
Circulation. 2004; 110: 1387-1391
61． Kosuge M, Miyajima E, Kimura K, et al. Comparison of atrial natriuretic peptide versus nitroglycerin for reducing blood pressure in acute myocardial infarction. Am J Cardiol. 1998; 81:
781-784
62． Kasama S, Toyama T, Kumakura H, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nuclear Med. 2004; 45: 1108-1113
63． Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001; 37: 1820-1826
64． The CAST investigators. Preliminary report; Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412
65． The Cardiac Arrhythmia Suppression Trial II Investigators.
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992; 327: 227-233 66． Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of
low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet. 1994; 344(8921): 493-498
67． 小川聡編「抗不整脈ガイドライン- CD-ROM 版ガイドラ
インの解説とシシリアンガンピットの概念」抗不整脈ガイ ドライン委員会編，20 項，ライフメディコム，東京，
2000
68． Aoyama N, Izumi T, Hiramori K, et al. Japanese Investigators of Fulminat Myocarditis: National survey of fulminate myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminate myocarditis (special report form a scientific committee) Circ J. 2002; 66: 133-144
69． Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res. 1959; 7: 649-657 70． Girou E, Brun-Buisson C, Taille S, et al. Secular trends in
nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. JAMA. 2003; 290: 2985-2991
71． Takano T, Endo T, Tanaka K, et al. Effects of positive end-expiratory pressure ventilation and extracorporeal ultrafiltration method in patients with refractory heart failure. Jpn Circ J. 1986;
50: 359-367
72． MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collectable task force facilitated by the American College of Chest Physicians: the American Association for Respiratory Care: and The American College of Critical Care Medicine.
Chest. 2002; 120(Suppl 6): 375S-395S
73． Williams MR, Oz MC. Indications and patient selection for mechanical ventricular assistance. Ann Thorac Surg 2001; 71 (Suppl 3): S86-S91
74． Christenson JT, Simonet F, Badel P, et al. Optimal timing of preoperative intraaortic balloon pump support in high-risk coronary patients. Ann Thorac Surg. 1999; 68: 934-939 75． Oz MC, Goldstein DJ, Pepino P, et al. Screening scale
predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995; 92(9Suppl):
II169-II173
76． Masai T, Sawa Y, Ohtake S, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg. 2002; 73: 549-555 77． Kantrowitz A, Wasfie T, Freed PS, et al. Intraaortic balloon
pumping 1967through 1982: analysis of complications in 733 patients. Am J Cardiol. 1986; 57: 976-983
78． Phillips SJ, Ballentine B, Slonine D, et al. Percutaneous initiation of cardiopulmonary bypass. Ann Thorac Surg. 1983;
36: 223-225
79． 松田 暉: 新版 経皮的心肺補助法PCPS の最前線. 秀潤 社, 東京, 2004.
80． Hata M, Shiono M, Orime Y, et al. Strategy of circulatory support with percutaneous cardiopulmonary support. Artif Organs. 2000: 24: 636-639
81． Kyo S, Motoyama T, Miyamoto N, et al. Percutaneous introduction of left atrial cannula for left heart bypass: utility of biplane transesophageal echocardiographic guidance for transseptal puncture. Artif Organs. 1992; 16: 386-391
82． Shibuya M, Kitamura M, Kurihara H, et al. Significant left ventricular unloading with transaortic catheter venting during venoarterial bypass. Artif Organs. 1997; 21: 789-792
83． Matsuda H, Matsumiya G. Current status of left ventricular assist devices: the role in bridge to heart transplantation and future perspectives. J Artif Organs 2003; 6: 157-161
84． 循環器病の診断と治療に関するガイドライン（2002 -2003年度合同研究班報告）循環器疾患における抗凝固・
抗血小板療法に関するガイドライン Cir J. 2004 68（supple IV）: 1153-1219
85． 松宮護郎，宮本裕治，松田 暉: 末期心不全に対する左 室補助人工心臓: 体内埋め込み型の有用性と問題点. 循環器 専門医. 2003; 第11巻第1号59-64
86． Dagenais F, Portner PM, Robbins RC, et al. The Novacor left ventricular assist system: clinical experience from the Novacor registry. J Card Surg. 2001; 16: 267-271
87． Jansen PGM, Wheeldon DR, Portner PM. Long term home discharge support with Novacor LVAS. J Heart Lung Transplant
1999; 18: 67(abstr)
88． Loisance DY, Jansen PG, Wheeldon DR, et al. Long-term mechanical circulatory support with the wearable Novacor left ventricular assist system. Eur J Cardiothorac Surg. 2000; 18:
220-224
89． Muller J, Wallkat G, Weng Y, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997; 96: 542-549
90． Hetzer R, Muller JH, Weng Y, et al. Bridging-to-recovery.
Ann Thorac Surg. 2001; 71(3Suppl): S109-S115
91． Frazier OH, Myers TJ, Westaby S, et al. Use of the Jarvik 2000left ventricular assist system as a bridge to heart transplantation or as destination therapy for patients with chronic heart failure. Ann Surg. 2003; 237: 631-636
92． Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol. 1998; 32: 1825-1831
93． Bakker PF, Meijburg H, De Jonge N, et al. Beneficial effects of biventricular pacing in congestive heart failure. PACE. 1994;
17: 820(abstr)
94． Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;
346: 1845-1853
95． Salukhe TV, Francis DP, Sutton R. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all cause mortality and hospitalization. Int J Cardiol. 2003; 87: 119-120
96． Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST).
Circulation. 2001; 103: 2055-2059
97． Nakanishi K, Hirasawa H, Sugai T, et al. Efficacy of continuous hemodiafiltration for patients with congestive heart failure. Blood Purif. 2002; 20: 342-348
98． 平澤博之，菅井桂雄，織田成人，他：CHDF による
humoral mediator の除去は有効である：集中治療1997; 9:
786-796
99． Singh S, Wann LS, Schuchard GH, et al. Right ventricular and right atrial collapse in patients with cardiac tamponade - a combined echocardiographic and hemodynamic study.
Circulation. 1984; 70: 966-971
100． Krikorian JG, Hancock EW. Pericardiocentesis. Am J Med.
1978; 65: 808-814
101． Spodick DH. Acute cardiac tamponade. New Eng J Med.
2003; 349: 684-690
102． Tsang TS, Enriquez-Sarano M, Freeman WK, et al.
Consecutive 1127therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21years. Mayo Clin Proc. 2002; 77: 429-436 103． Hasbun R, Vikram HR, Barakat LA, et al. Complicated left-sided native valve endocarditis in adults. Risk classification for mortality. JAMA. 2003; 289; 1933-1940
104． Bauernschmitt R, Jakob HG, Vahl CE, et al. Operation for infective endocarditis: results after implantation of mechanical valves. Ann Thorac Surg. 1998; 65: 359-364
105． Zegdi R, Debieche M, Latermouille C, et al. Long term results of mitral valve repair in active endocarditis. Circulation. 2005;
111: 2532-2536
106． Padro JM, Mesa JM, Silvestre J, et al. Subacue cardiac rupture: repair with a sutureless technique. Ann Thorac Surg.
1993; 55: 20-23
107． Sakakibara T, Matsuwaka R, Shintani H, et al. Successful repair of postinfarction left ventricular free wall repture: new strategy with hypothermic percutaneous cardiopulmonary bypass. J Thorac Cardovasc Surg. 1996; 111: 276
108． Cobbs BW, Hatcher CR, Robinson PH. Cardiac Rupture.
Three operations with two long-term survivals. JAMA. 1973;
223: 532-535
109． Sutherland FW, Guell FJ, Pathi VL, et al. Postinfarction ventricular free wall rupture: strategies for diagnosis and treatment. Ann Thorac Surg. 1996; 61: 1281-1285
110． Daggett WM, Guyton RA, Mundth ED, et al. Surgery for post-myocardial infarct ventricular septal defect. Ann Surg.
1977; 186: 260-271
111． David TE, Dale L, Sun Z. Postinfarction ventricular septal rupture: repair by endocardial patch with infarct exclusion. J Thorac Cardiovasc Surg. 1995; 110: 1315-1322
112． Deja MA, Szostek J, Widenka K, et al. Post infarction ventricular septal defect - can we do better - Eur J Cardiothorac Surg. 2000; 18: 194-201
113． Pett SB Jr., Folllis F, Allen K, et al. Posterior ventricular septal rupture: an anatomical reconstruction. J Card Surg. 1998;
13: 445-450
114． Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction.
Circulation. 2000; 101: 27-32
115． Komeda M, Fremes SE, David TE. Surgical repair of postinfarction ventricular septal defect. Circulation. 1990; 82 (suppl 5): IV243-IV247
116． Gillinov AM, Wierup PN, Blackstone EH, et al. Is repair preferable to replacement for ischemic mitral regurgitation? J Thoracic Cardiovasc Surg. 2001; 122: 1125-1141
117． Maisano F, Torracca L, Oppizzi M, et al. The edge-to-edge technique: a simplified method to correct mitral insufficiency.
Eur J Cardiothorac Surg. 1998; 13: 240-245
118． Katz AM. Potential deleterious effects of inotopic agents in the therapy of chronic heart failure. Circulation. 1986; 73(3Pt 2): III184-III190
119． Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol. 1993; 22(suppl 4A): 119A-126A
120． Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;
4: 515-529
121． Lee L, Erbel R, Brown TM, et al. Multicenter registry of angioplasty therapy of cardiogenic shock: Initial and long - term survival. J Am Coll Cardiol. 1991; 17: 599-603
122． Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock
complicating acute myocardial infarction. J Am Coll Cardiol.
1992; 19: 907-914
123． Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999; 341: 625-634
124． Gray RJ, Sethna D, Matloff JM. The role of cardiac surgery in acute myocardial infarction with mechanical complications. Am Heart J. 1983; 106(4Pt 1): 723-735
125． Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol. 1992; 70: 147-151
126． Lehmann KG, Francis CK, Dodge HT. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection and prognostic implications. The TIMI Study Group. Ann Intern Med. 1992; 117: 10-17
127． The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;
337: 1576-1583
128． Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone.
Circulation. 2000; 101: 1297-1302
129． Kuck KH, Cappato R, Siebels J, et al. for the CASH Investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102: 748-754
130． Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials:
antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol. 2004; 19:
26-30
131． Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med.
1996; 335: 1933-1940
132． Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341: 1882-1890
133． Khan MG. Complication of myocardial infarction and postinfarction care. In Heart Disease Diagnosis and Therapy (Khan MG, Marriott HJL, et al ed), Williams & Wilkins, Baltimore, 1996; 61-74
134． 浅野竜太，住吉徹也. 心筋梗塞における心不全. 実地診療 に則した心不全診断・治療マニュアル（高野照夫，清野精 彦 編）2002; 108-114
135． 日本高血圧治療学会高血圧治療ガイドライン作成委員会
「高血圧治療ガイドライン2004」ライフサイエンス, 東 京, 2004
136． Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given
for hypertensive emergencies and pseudoemergencies? JAMA.
1996; 276: 1328-1331
137． Hamada M, Shigematsu Y, Ikeda S, et al. Class Ia antiarrhythmic drug, cibenzoline: a new approach to medical treatment of hypertrophic obstructive cardiomyopathy.
Circulation. 1997; 96: 1520-1524
138． Fananapazir L, Cannon RO 3rd, Tripodi D, et al. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation. 1992;
85: 2149-2161
139． Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg. 1999; 47: 94-100 140． Rathore SS, Wang Y, Krumholz HM. Sex-based differences
in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002; 347: 1403-1411
141． Young JB, Abraham WT, Smith AL, et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003; 289:
2685-2694
142． Wilkoff BL, Cook JR, Epstein AE, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002; 288:
3115-3123
143． 急性および慢性心筋炎の診断・治療に関するガイドライ ンCirc J. 2004; 68（Suppl IV）: 1231-1263
144． Brown CA, O'Connell JB. Implications of the myocarditis treatment trial for clinical practice. Curr Opin Cardiol. 1996; 11:
332-336
145． Kodama M, Okura Y, Hirono S, et al. A new scoring system to predict the efficacy of steroid therapy for patients with acute myocarditis- a retrospective study. Jpn Circ J. 1998; 62: 715-720 146． Caforio AL, McKenna WJ. Recognition and optimum
management of myocarditis. Drugs. 1996; 52: 515-525 147． Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin
treatment of acute myocarditis in the pediatric population.
Circulation. 1994; 89: 252-257
148． 日本循環器学会学術委員会（1997-1999年度報告）心肺 補助循環を用いた劇症型心筋炎の治療と予後に関する調査 研究. Jpn Circ J. 2000; 64（Suppl I）: 985-992
149． 弁膜症の非薬物療法に関するガイドライン（2000-2001 年度合同研究班報告）Circ J. 2002; 66（Suppl IV）: 1261-1323
150． Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease) . ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol.
1998; 32: 1486-1588
151． The National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry Participants. Multicenter experience with balloon mitral commissurotomy. NHLBI Balloon Valvuloplasty